High Purity Pharmaceutical Raw Material Medicine Purity Entecavir Powder CAS 142217-69-4

Entecavir is a cyclopentyl guanosine analog launched for the once-daily oral treatment of chronic hepatitis B virus (HBV) infection, and it is the third nucleoside or nucleotide analog to be marketed for this indication. Lamivudine, a deoxythiacytosine analog, and adefovir dipivoxil, a nucleotide analog, have been marketed since 1998 and 2002, respectively. Entecavir and adefovir are specifically indicated for HBV, whereas lamivudine is indicated for both HBV and HIV infections. In mammalian cells, entecavir is efficiently phosphorylated to the active triphosphate form, which competes with the natural substrate deoxyguanosine triphosphate and functionally inhibits all three activities of the HBV polymerase: (1) base priming, (2) reverse transcription of the negative strand from the pregenomic messenger RNA, and (3) synthesis of the positive strand of HBV DNA.The most common adverse events associated with the use of entecavir are similar to those typically seen with HBV therapy and include headache, abdominal pain, diarrhea, fatigue, and dizziness.

Function:

Entecavir Hydrate is a new kind of cyclopentyl acyl guanosine anti-hepatitis b virus drugs with its pharmacological effects similar as entecavir. It is clinically applied to the treatment of adult chronic hepatitis b in which there is active viral replication, increased serum transaminase ALT or active lesions showed from liver histology. 
Entecavir Monohydrate is a kind of analogues of guanine nucleoside which has inhibitory on the polymerase of hepatitis b virus (HBV). It can become active triphosphate salts through phosphorylation. The triphosphate salt has a half-life of 15 hours inside a cell. Through completion with the natural substrates of HBV polymerase, guanine nucleoside triphosphate, entecavir triphosphate can suppress all the three types of activities of the virus polymerase (reverse transcriptase): 
(1) The initiation of HBV polymerase.
(2) The formation of the negative chain of reverse transcription of the pre-genome.
(3) The synthesis of HBVDNA positive chain.

Shaanxi TNJONE Pharmaceutical Co., Ltd is a high-tech enterprise mainly engaged inthe development and sale of pharmaceutical chemical raw materials and relatedproducts.The company has advanced and perfect supporting system,forming advancedchemical synthesis technology, which can quickly meet the individual needs and serialdevelopment from suitable detection to industrial production.Qur business covers morethan 30 countries, most of customers from Europe, Southeast Asia and other countriesin the world, we can guarantee the quality and price. Our enterprise purpose is basedon the market, strengthen strength, take the road of scientific environmental protectionand sustainable development, rely on the country. The company has a strong financialstrength and a good business environment, can provide customers with quality,efficientand fast service.

1.High quality and competitive price.
2.Free sample for your evaluation.
3.Promptly delivery by well-reputed shipping lines.
4.Trial order is available for testing after samples.
5.We will inform you all the information at every stage in advance.
6.Packaging can gear to buyers' special request.